GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » EPS without NRI

BioSpecifics Technologies (BioSpecifics Technologies) EPS without NRI : $2.36 (TTM As of Sep. 2020)


View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies EPS without NRI?

BioSpecifics Technologies's earnings per share without non-recurring items for the three months ended in Sep. 2020 was $0.73. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36.

During the past 12 months, BioSpecifics Technologies's average earnings per share (NRI) Growth Rate was -25.60% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 26.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 35.20% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for BioSpecifics Technologies's EPS without NRI or its related term are showing as below:

BSTC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.9   Med: 21.1   Max: 105.3
Current: 26.5

During the past 13 years, BioSpecifics Technologies's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 105.30% per year. The lowest was -59.90% per year. And the median was 21.10% per year.

BSTC's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 4.7 vs BSTC: 26.50

BioSpecifics Technologies's EPS (Diluted) for the three months ended in Sep. 2020 was $0.73. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36.

BioSpecifics Technologies's EPS (Basic) for the three months ended in Sep. 2020 was $0.73. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2020 was $2.36.


BioSpecifics Technologies EPS without NRI Historical Data

The historical data trend for BioSpecifics Technologies's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies EPS without NRI Chart

BioSpecifics Technologies Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 1.56 1.55 2.73 3.33

BioSpecifics Technologies Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 1.00 0.61 0.02 0.73

Competitive Comparison of BioSpecifics Technologies's EPS without NRI

For the Biotechnology subindustry, BioSpecifics Technologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSpecifics Technologies's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's PE Ratio without NRI falls into.



BioSpecifics Technologies EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioSpecifics Technologies  (NAS:BSTC) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


BioSpecifics Technologies EPS without NRI Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Traded in Other Exchanges
N/A
Address
35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Executives
Paul Gitman director 167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth director 191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman director, 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman director 43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N. director DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison officer: Chief Financial Officer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi director, officer: Chief Executive Officer 41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell officer: Principal Financial Officer C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law officer: SVP Business Development 23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman director, 10 percent owner, officer: President 1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487

BioSpecifics Technologies (BioSpecifics Technologies) Headlines

From GuruFocus